Sirolimus · Hyftor, AY-22989

What is Sirolimus?

Sirolimus is a macrocyclic lactone that binds FK Binding Protein-12 to inhibit mTOR, suppressing T-lymphocyte activation and proliferation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Hyftor, AY-22989, NSC-226080, eRapa (encapsulated rapamycin)

Drug type

Small molecule

Targets

mammalian target of rapamycin (MTOR), FK Binding Protein-12 (FKBP1A) (binding partner it blocks)

Mechanism

Inhibitor of mammalian target of rapamycin (MTOR)

Pathways

T-cell proliferation, mTOR signaling, angiogenesis, cell cycle progression

Therapy area

Oncology

Developer

Pf Prism Cv

In trials of

BDRX

FDA status

Approved as Hyftor (September 15, 1999), NDA021083 · FDA label

UNII

W36ZG6FT64

✅ FDA-approved uses

• Prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants
• Treatment of patients with lymphangioleiomyomatosis
• Treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older

From the indications section of the FDA label (version of Mar 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Familial Adenomatous Polyposis (FAP)

Other drugs acting on MTOR

Sources

• FDA label (DailyMed)
• FDA label Sirolimus (2026-03-26), indications
• FDA label Hyftor (2025-08-22), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT06950385

Updated Oct 3, 2026.